Shimadzu launches amyloid mass spectrometry service

LabPulse.com staff writers
Jul 10, 2022
2022 07 11 16 26 9131 Shimadzu Rsna 2019 400

Shimadzu has announced the commercialization of its Amyloid Mass Spectrometry (MS) Service for the early detection of amyloid-positive individuals.

The new approach predicts abnormal amyloid-beta concentration, which can be an indicator of amyloid pathology in the brain, the firm said.

By enabling the reliable characterization of amyloid pathology in the brain, the blood-based method can assist in the development of pharmaceutical treatments for Alzheimer's disease.

Furthermore, the analysis is opening the door for new advances in research, identifying suitable candidates for clinical trials, and assisting pharmaceutical companies in their testing of candidate drugs, the firm said, adding that the method is suitable for large-scale deployment.

Latest in Brain Disease
2019 04 30 23 29 0302 Brain 400
Labcorp NfL test confirms neurodegenerative disease
July 12, 2022
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
2022 05 04 20 54 3251 Computer Brain Hemisphere 400
FDA grants approval for Fujirebio assay for Alzheimer's plaques
May 3, 2022
2022 03 10 18 19 1134 Mri Head 400
Insightec to launch new trials of Exablate Neuro
March 9, 2022
Related Stories
Xevo Tq Absolute Esi I Class Angle 01 Sml Crop
Mass Spec
Waters introduces next-generation mass spectrometer for clinical diagnostic applications
2022 03 01 23 02 5066 Older Woman Anxious 400
Alzheimer's
Does race affect interpretation of Alzheimer's disease tests?
2022 03 02 20 27 6315 2022 03 04 Tau Biomarkers 400
Alzheimer's
Spinal fluid tests may aid PET scans of Alzheimer's disease
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Brain Disease
Labcorp NfL test confirms neurodegenerative disease
By LabPulse.com staff writers
The neurofilament light chain (NfL) blood test will allow doctors to identify and verify signs of neurodegenerative disease, enabling physicians to provide a more effective and efficient path to diagnosis and treatment for patients, the firm said.
July 12, 2022
2019 04 30 23 29 0302 Brain 400
New biomarker could detect early Alzheimer’s before symptoms
By Joseph Constance
In addition, the findings have some implications for taking brain-boosting dietary supplements that contain the amino acid serine. The key compound responsible for producing serine in the body is PHGDH. The scientists reported that PHGDH mRNA and protein levels had increased in the brains of two mouse models of Alzheimer's disease or tauopathy.
May 4, 2022
2022 05 05 18 49 5180 Patient Elderly Confused Headache 400
FDA grants approval for Fujirebio assay for Alzheimer's plaques
By Brian Casey
The FDA granted clearance under its breakthrough device pathway to Fujirebio's Lumipulse G β-Amyloid Ratio (1-42/1-40) test, which is designed to measure the ratio of β-amyloid 1-42 and β-amyloid 1-40. These are proteins that can accumulate and form plaques in the brain; concentrations of these proteins can be detected in cerebral spinal fluid (CSF).
May 3, 2022
2022 05 04 20 54 3251 Computer Brain Hemisphere 400
Insightec to launch new trials of Exablate Neuro
By LabPulse.com staff writers
One study will evaluate the use of Exablate Neuro to treat patients with primary non-small cell lung cancer that has metastasized to the brain in conjunction with Keytruda, a humanized antibody immunotherapy. Exablate Neuro could be used to open up the blood-brain barrier to make immunotherapy agents like Keytruda more effective.
March 9, 2022
2022 03 10 18 19 1134 Mri Head 400
Spinal fluid tests may aid PET scans of Alzheimer's disease
By Will Morton
A Swiss group led by senior author Michael Schöll, PhD, of the University Gothenburg investigated whether fluid and blood biomarkers that indicate Alzheimer's disease could predict the accumulation of neurofibrillary tau tangles seen on PET scans in patients diagnosed with the disease. They found the lab tests performed well enough to help select patients for PET imaging studies evaluating new treatments.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.Associations of baseline beta-amyloid PET and baseline phosphorylated tau-181 (p-tau181) with F-18 flortaucipir (FTP) Standardized uptake value ratio (SUVR) annualized change for (A) cognitively unimpaired and (B) cognitively impaired individuals. Brain surface renderings depict Pearson correlation coefficients adjusted for age and sex (r) representing the strength of the association between the different biomarkers and F-18 flortaucipir SUVR change in each brain region. The right upper panel represents age- and sex-adjusted Pearson correlation coefficients (r), along with p-values, for the association between the biomarkers and F-18 flortaucipir SUVR change in the Alzheimer's disease meta-region of interest (ROI). The root mean squared error (RMSE) for the prediction of F-18 flortaucipir SUVR change by a linear model with the biomarker as predictor and age and sex as covariates. RMSE was estimated using leave-one-out cross-validation. Voxel-wise statistical maps were thresholded using more lenient cluster-forming thresholds of p < 0.05 (uncorrected) at the voxel level and further thresholded at the cluster level by restricting results to clusters with a number of voxels higher than the expected number of voxels as predicted using random field theory. Image courtesy of Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
March 3, 2022
2022 03 02 20 27 6315 2022 03 04 Tau Biomarkers 400
NeuroVision receives funding to develop dementia blood test
By LabPulse.com staff writers
The Sacramento, CA-based company will develop an "ultramultiplex assay" to measure multiple blood biomarkers that are associated with the development of dementia, it said. Additionally, the project will further NeuroVision's work on a proprietary blood assay that appears to mirror beta-amyloid protein load in the brain, the company noted.
August 23, 2021
2021 08 24 22 29 3700 Woman Senior Citizen 400
BrainChip, NaNose laud progress in breath sample COVID-19 test
By LabPulse.com staff writers
The test incorporates NaNose Medical's sensor array to collect data and BrainChip's Akida artificial intelligence chip to perform the diagnosis, according to the two firms. NaNose's sensory array is based on technology developed at Technion Israel Institute of Technology in Haifa, and has similar sensitivity to minute quantities of volatile organic compounds (VOCs) as a dog's nose.
February 24, 2021
2021 02 25 23 48 3444 Covid Virus Dna Molecule 400
AI-based test diagnoses dental infection-related brain abscess
By Melissa Busch
The algorithm-based pathogenic sequencing technique, which provides quicker, more precise results than traditional lab bacterial cultures, showed that several types of bacteria that can colonize the oral cavity were found in the 53-year-old woman's brain and spinal cord fluid. She was diagnosed with ventricular and spinal canal empyema, which is rarely seen today due to medical advances.
August 20, 2020
2020 06 29 16 41 7549 Pathogenic Bacteria Viruses 400
FDA approves Avid's PET agent for tau pathology imaging
By LabPulse.com staff writers
Tauvid is indicated for adult patients with cognitive impairment who are being evaluated for Alzheimer's disease. The PET radiopharmaceutical helps clinicians estimate the density and distribution of tau neurofibrillary tangles in the brain, which are a marker of Alzheimer's disease.
May 28, 2020
2019 02 13 19 24 5396 Fda Logo V2 400
Gene biomarker shows promise as alternative early Alzheimer's blood test
By Emily Hayes
The group evaluated extracellular RNA (exRNA) in plasma samples from 35 study participants who had confirmed Alzheimer's disease based on postmortem pathological brain examinations and who had been followed for 15 years prior to death. Of the total, nine had not been symptomatic and served as controls.
March 31, 2020
2020 03 31 23 03 5810 Brain Dementia Leaves 400
Blood samples, PET imaging link brain injuries to chronic encephalopathy
By Wayne Forrest
Researchers observed elevated levels of tau tangles and a certain blood chemical associated with traumatic brain injury (TBI), both of which could indicate current or future acute brain degeneration and possible progression to CTE as a result of brain injury from an improvised explosive device (IED).
February 26, 2020
2019 04 30 23 29 0302 Brain 400
Blood test helps gauge patients' CSVD risk
By LabPulse.com staff writers
The research could help develop a "novel diagnostic test that clinicians can start to use as a quantitative measure of brain health in people who are at risk of developing cerebral small vessel disease," lead author Dr. Jason Hinman said in a statement released by the university.
February 4, 2020
2020 02 04 23 47 3781 2020 02 04 White Matter Thumb
Page 1 of 2
Next Page